Pentraxin-3 as a marker of sepsis severity and predictor of mortality outcomes: A systematic review and meta-analysis

Lee, Yee Ting; Gong, Mengqi; Chau, Alex; Wong, Wing Tak; Bazoukis, George; Wong, Sunny H.; Λαμπρόπουλος, Κωνσταντίνος; Xia, Yunlong; Li, Guangping; Wong, Martin C.S.; Liu, Tong; Wu, William Ka Kei; Tse, Gary

doi:10.1016/j.jinf.2017.10.016

Cited by 64 publications

(53 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For example, those patients with initially high PAI-1 levels may be offered a more proactive management, including early ICU admission, initiation of fluid resuscitation, and inotropic support. Its diagnostic and prognostic value in combination with other plasma biomarkers needs to be elucidated in future studies ( 32 – 34 ).…”

Section: Discussionmentioning

confidence: 99%

Plasminogen Activator Inhibitor 1 for Predicting Sepsis Severity and Mortality Outcomes: A Systematic Review and Meta-Analysis

Tipoe

Chung

et al. 2018

Front. Immunol.

Self Cite

View full text Add to dashboard Cite

ObjectivesPlasminogen activator inhibitor-1 (PAI-1), a crucial regulator of fibrinolysis, is increased in sepsis, but its values in predicting disease severity or mortality outcomes have been controversial. Therefore, we conducted a systematic review and meta-analysis of its predictive values in sepsis.MethodsPubMed and Embase were searched until August 18, 2017 for studies that evaluated the relationships between PAI-1 levels and disease severity or mortality in sepsis.ResultsA total of 112 and 251 entries were retrieved from the databases, of which 18 studies were included in the final meta-analysis. A total of 4,467 patients (36% male, mean age: 62 years, mean follow-up duration: 36 days) were analyzed. PAI-1 levels were significantly higher in non-survivors than survivors [odds ratios (OR): 3.93, 95% confidence interval (CI): 2.31–6.67, P < 0.0001] and in patients with severe sepsis than in those less severe sepsis (OR: 3.26, 95% CI: 1.37–7.75, P = 0.008).ConclusionPAI-1 is a significant predictor of disease severity and all-cause mortality in sepsis. Although the predictive values of PAI-1 reached statistical significance, the clinical utility of PAI-1 in predicting outcomes will require carefully designed prospective trials.

show abstract

Section: Discussionmentioning

confidence: 99%

Plasminogen Activator Inhibitor 1 for Predicting Sepsis Severity and Mortality Outcomes: A Systematic Review and Meta-Analysis

Tipoe

Chung

et al. 2018

Front. Immunol.

Self Cite

View full text Add to dashboard Cite

show abstract

“…The end result is a pro‐arrhythmic substrate for arrhythmogenesis. As with other disorders, blood markers have been used for risk stratification purposes . More recently, galectin‐3, which is raised in the context of myocardial fibrosis, inflammation, and immune response activation, has emerged as a promising biomarker for risk stratification .…”

Section: Introductionmentioning

confidence: 99%

“…As with other disorders, blood markers have been used for risk stratification purposes. [2][3][4][5][6][7] More recently, galectin-3, which is raised in the context of myocardial fibrosis, inflammation, and immune response activation, has emerged as a promising biomarker for risk stratification. 8 A recent meta-analysis has demonstrated that galectin-3 provides incremental prognostic value that extends beyond that of traditional risk factors in the context of heart failure.…”

Section: Introductionmentioning

confidence: 99%

Galectin‐3 and risk of atrial fibrillation: A systematic review and meta‐analysis

Gong

Cheung

Wang

et al. 2020

Clinical Laboratory Analysis

Self Cite

View full text Add to dashboard Cite

Background Galectin‐3 is an inflammatory marker that is raised in myocardial fibrosis and inflammation. Recent studies have explored its role in predicting atrial fibrillation (AF) outcomes. The aim of this systematic review and meta‐analysis is to examine the association between serum concentration of galectin‐3 and AF. Methods PubMed, EMBASE, and the Cochrane Database were searched. A total of 280 studies were identified, of which 28 studies involving 10 830 patients were included in our meta‐analysis. Results Galectin‐3 is present at higher concentrations in patients with AF than those in sinus rhythm (mean difference [MD] = −0.68 ng/mL, 95% CI: −0.92, −0.44, Z = 5.61, P < .00001). Galectin‐3 levels were significantly higher in the persistent AF than in the paroxysmal AF group (MD = −0.94 ng/mL, 95% CI: −1.85, −0.03, Z = 2.04, P = .04). Higher galectin‐3 levels were associated with a 45% increase in the odds of developing AF (odds ratio [OR] = 1.45, 95% CI: 1.15, 1.83, Z = 3.11, P = .002) and risk of AF recurrence (hazard ratio [HR] =1.17, 95% CI: 1.06, 1.29, Z = 3.12, P = .002). Conclusions Our meta‐analysis found that galectin‐3 is significantly higher in patients with persistent AF than in those with paroxysmal AF, and can predict both AF development and recurrence after treatment.

show abstract

“…Pentraxin plays an important role in angiogenesis by modulating the secretion of vascular epidermal growth factor-2 (VEGF-2) and fibroblast growth factor (FGF) [6]. The prognostic importance of PTX was confirmed in the prediction of deaths from various causes among patients with sepsis [7,8]. It is also suggested that the increase of PTX3 level in blood may be connected with smoking [3].…”

Section: Introductionmentioning

confidence: 98%

Clinical usefulness of pentraxin 3 (PTX3) as a biomarker of acute pancreatitis and pancreatic cancer

Głuszek¹,

Matykiewicz²,

Grabowska³

et al. 2020

View full text Add to dashboard Cite

Introduction: Increased concentrations of pentraxin 3 (PTX 3) were diagnosed in acute pancreatitis (AP) and in pancreatic ductal adenocarcinoma (PDAC). Aim of the research: To assess of the clinical usefulness of PTX3 in the early differentiation of AP from PDAC. Material and methods: The test group consisted of 125 patients with AP and 24 people with PDAC, as well as 52 healthy subjects. The following concentrations were tested in plasma: PTX3, C-reactive protein (CRP), interleukin-6 (IL-6), and CA-19.9. Results: The mean PTX3 concentration in the moderately-severe AP (MAP) or severe AP (SAP) equalled 16.53 ng/ml and was significantly higher in comparison with mild AP (9.60 ng/ml; p = 0.0007) and the control group (2.31 ng/ml). In the case of patients with PDAC, the mean concentration of PTX3 was 9.20 ng/ml and was significantly higher than in the control group (2.31 ng/ml); p < 0.0001. A significantly higher average CRP value of 100.37 mg/l and IL-6 91.65 pg/ml was also found in patients with PDAC compared to the control group (p < 0.0001). Tested pro-inflammatory cytokines were significantly higher in patients with MAP or SAP than in those with PDAC (p < 0.05). The ROC curve confirms the clear connection of PTX3 level and PDAC in comparison with the control group (p = 0.0001), relatively low sensitivity, and high specificity. However, the results were not significant enough to allow us to differentiate cancer from AP (p > 0.05). Conclusions: Pentraxin 3 can be a marker in the prediction of the severe course of AP, but its clinical usefulness for the differentiation of PDAC was not confirmed. Streszczenie Wprowadzenie: Podwyższone stężenie pentraksyny 3 (PTX3) stwierdzono zarówno w ostrym zapaleniu trzustki (AP), jak i raku trzustki (PDAC). Cel pracy: Ocena przydatności klinicznej PTX3 we wczesnym różnicowaniu AP i PDAC. Materiał i metody: Zbadano 125 chorych na AP i 24 chorych z potwierdzonym histopatologicznie lub cytologicznie PDAC oraz 52 osoby zdrowe jako grupę kontrolną. Próbkę krwi pobierano w pierwszym dniu hospitalizacji. Oznaczono stężenia w osoczu PTX3, białka C-reaktywnego (CRP), interleukiny (IL-6) i aktywność CA-19.9. Wyniki: Średnie stężenie PTX3 u pacjentów z umiarkowanie ciężkim AP (MAP) i ciężkim AP (SAP) wynosiło 16,53 ±15,73 ng/ml i było istotnie wyższe niż średnie stężenia u pacjentów z łagodnym AP (9,60 ±9,65 ng/ml; p = 0,0007) i z grupy kontrolnej (2,31 ±0,58 ng/ml). Średnie stężenie PTX3 u chorych z PDAC wynosiło 9,20 ng/ml i było znacząco większe niż stężenie w grupie kontrolnej (2,31 ng/ml); p < 0,0001. Stwierdzono również istotnie wyższą średnią wartość CRP 100,37 mg/l i IL-6 91,65 pg/ml u chorych z PDAC w porównaniu z grupą osób zdrowych (p < 0,0001). Stężenia cytokin prozapalnych były znamiennie wyższe u chorych z MAP i SAP niż z PDAC (p < 0,05). Krzywa ROC potwierdza istotną zależność między stężeniem PTX3 a rozpoznaniem PDAC w porównaniu z grupą kontrolną, ze stosunkowo niską czułością i wysoką specyficznością. Nie wykazano istotnej zdolności do różnicowania PDAC z AP (p > 0,05). ...

show abstract

Pentraxin-3 as a marker of sepsis severity and predictor of mortality outcomes: A systematic review and meta-analysis

Cited by 64 publications

References 47 publications

Plasminogen Activator Inhibitor 1 for Predicting Sepsis Severity and Mortality Outcomes: A Systematic Review and Meta-Analysis

Plasminogen Activator Inhibitor 1 for Predicting Sepsis Severity and Mortality Outcomes: A Systematic Review and Meta-Analysis

Galectin‐3 and risk of atrial fibrillation: A systematic review and meta‐analysis

Clinical usefulness of pentraxin 3 (PTX3) as a biomarker of acute pancreatitis and pancreatic cancer

Contact Info

Product

Resources

About